6-bromo-7-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridine | 1365645-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-bromo-7-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridine
• CAS: 1365645-31-3
• 化学式: C₁₉H₂₀BrClN₄O
• 分子量: 435.751
• InChiKey: AITCLJHEQHOUPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  54
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-7-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridine 、 1,3-丙二胺 以 正丁醇 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases

  摘要：

  The design, synthesis and biological evaluation of a series of azabenzimidazole derivatives as TBK1/IKK epsilon kinase inhibitors are described. Starting from a lead compound 1a, iterative design and SAR exploitation of the scaffold led to analogues with nM enzyme potencies against TBK1/IKK epsilon. These compounds also exhibited excellent cellular activity against TBK1. Further structure-based design to improve selectivity over CDK2 and Aurora B resulted in compounds such as 5b-e. These probe compounds will facilitate study of the complex cancer biology of TBK1 and IKK epsilon. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.018
• 作为产物：
  描述：

  5-溴-4-氯吡啶-2,3-二胺 、 4-[2-(1-哌啶基)乙氧基]-苯甲酸 在 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 6-bromo-7-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-1H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases

  摘要：

  The design, synthesis and biological evaluation of a series of azabenzimidazole derivatives as TBK1/IKK epsilon kinase inhibitors are described. Starting from a lead compound 1a, iterative design and SAR exploitation of the scaffold led to analogues with nM enzyme potencies against TBK1/IKK epsilon. These compounds also exhibited excellent cellular activity against TBK1. Further structure-based design to improve selectivity over CDK2 and Aurora B resulted in compounds such as 5b-e. These probe compounds will facilitate study of the complex cancer biology of TBK1 and IKK epsilon. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.018

文献信息

• Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases
  作者：Tao Wang、Michael A. Block、Scott Cowen、Audrey M. Davies、Erik Devereaux、Lakshmaiah Gingipalli、Jeffrey Johannes、Nicholas A. Larsen、Qibin Su、Julie A. Tucker、David Whitston、Jiaquan Wu、Hai-Jun Zhang、Michael Zinda、Claudio Chuaqui

  DOI：10.1016/j.bmcl.2012.01.018

  日期：2012.3

  The design, synthesis and biological evaluation of a series of azabenzimidazole derivatives as TBK1/IKK epsilon kinase inhibitors are described. Starting from a lead compound 1a, iterative design and SAR exploitation of the scaffold led to analogues with nM enzyme potencies against TBK1/IKK epsilon. These compounds also exhibited excellent cellular activity against TBK1. Further structure-based design to improve selectivity over CDK2 and Aurora B resulted in compounds such as 5b-e. These probe compounds will facilitate study of the complex cancer biology of TBK1 and IKK epsilon. (C) 2012 Elsevier Ltd. All rights reserved.